Heart, Lung, and Blood Institute Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and

Copyright © 2006 American Heart Association. All rights reserved. Print ISSN: 0009-7322. Online 72514 Circulation is published by the American Heart Association. 7272 Greenville Avenue, Dallas, TX DOI: 10.1161/CIRCULATIONAHA.106.174516 2006;113;2363-2372 Circulation Kathryn A. Taubert Krumholz, Lori Mosca, Richard C. Pasternak, Thomas Pearson, Marc A. Pfeffer and Brass, Gregg C. Fonarow, Scott M. Grundy, Loren Hiratzka, Daniel Jones, Harlan M. Sidney C. Smith, Jr, Jerilyn Allen, Steven N. Blair, Robert O. Bonow, Lawrence M. Heart, Lung, and Blood Institute Other Atherosclerotic Vascular Disease: 2006 Update: Endorsed by the National AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and http://circ.ahajournals.org/cgi/content/full/113/19/2363 located on the World Wide Web at: The online version of this article, along with updated information and services, is

[1]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[2]  Joseph P Ornato,et al.  ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). , 2006, Journal of the American College of Cardiology.

[3]  O. Faergeman,et al.  High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.

[4]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[5]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[6]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[7]  E. Peterson,et al.  The Society of Thoracic Surgeons practice guideline series: aspirin and other antiplatelet agents during operative coronary revascularization (executive summary). , 2005, The Annals of thoracic surgery.

[8]  N. Abate,et al.  Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. , 2005, American heart journal.

[9]  M. Pfeffer,et al.  Angiotensin-converting-enzyme inhibition in stable coronary artery disease. , 2004, The New England journal of medicine.

[10]  David B Allison,et al.  Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. , 2004, Circulation.

[11]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[12]  Lippincott Williams Wilkins,et al.  ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction , 2004 .

[13]  J. Ornato,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Circulation.

[14]  Christopher P Cannon,et al.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.

[15]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[16]  Neil J Stone,et al.  Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines , 2004, Circulation.

[17]  R. Gliklich,et al.  Get with the guidelines for cardiovascular secondary prevention: pilot results. , 2004, Archives of internal medicine.

[18]  L. Mosca.  Summary of the American Heart Association’s Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Constance K Haan,et al.  Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women , 2004, Circulation.

[20]  Acip.  Prevention and control of influenza : recommendations of the Advisory Committee on Immunization Practices (ACIP) , 2004 .

[21]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Constance K Haan,et al.  Evidence-based guidelines for cardiovascular disease prevention in women. , 2004, Circulation.

[23]  Timothy J Gardner,et al.  ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). , 2004, Circulation.

[24]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. , 2003, Hypertension.

[25]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[26]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial , 2003, The Lancet.

[27]  M. Pfeffer,et al.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial , 2003, The Lancet.

[28]  N. Poulter,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial☆ , 2003 .

[29]  Fernando Costa,et al.  Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Ph , 2003, Circulation.

[30]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[31]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Circulation.

[32]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[33]  Sankey V. Williams,et al.  ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). , 2003, Journal of the American College of Cardiology.

[34]  Lawrence J Appel,et al.  Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. , 2003, Circulation.

[35]  Barry R. Davis,et al.  Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). , 2002, JAMA.

[36]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[37]  Carl J Pepine,et al.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients , 2002, Circulation.

[38]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[39]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[40]  L. Goldstein,et al.  Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) , 2002, Neurology.

[41]  Robert Parrish,et al.  Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. , 2002, JAMA.

[42]  Malbea A Lapete,et al.  Prevention and Control of Influenza Recommendations of the Advisory Committee on Immunization Practices ( ACIP ) , 2004 .

[43]  V. Fuster,et al.  AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Circulation.

[44]  V. Fuster,et al.  AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. , 2001, Journal of the American College of Cardiology.

[45]  K. Patrick,et al.  Physical Activity and Public Health: A Recommendation From the Centers for Disease Control and Prevention and the American College of Sports Medicine , 1995 .

[46]  T. Bolin,et al.  OF HEALTH , 2022 .